Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akero Therapeutics

42.72
-0.8600-1.97%
Pre-market: 42.00-0.7200-1.69%06:01 EDT
Volume:593.89K
Turnover:25.51M
Market Cap:3.40B
PE:-11.38
High:45.38
Open:45.38
Low:42.26
Close:43.58
Loading ...

Stock Track | Akero Therapeutics Plummets 8.06% on Disappointing Phase 2b Trial Results for Efruxifermin in MASH

Stock Track
·
16 Nov 2024

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

GlobeNewswire
·
16 Nov 2024

Bank of America Securities Reaffirms Their Hold Rating on Akero Therapeutics (AKRO)

TIPRANKS
·
12 Nov 2024

Akero Therapeutics Advances in MASH Treatment Trials

TIPRANKS
·
12 Nov 2024

Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Positive Outlook for Akero Therapeutics Driven by Efruxifermin’s Potential and Strategic Clinical Programs

TIPRANKS
·
12 Nov 2024

Akero Therapeutics: Promising Pipeline and Strong Financial Position Suggest Favorable Risk/Reward Profile

TIPRANKS
·
09 Nov 2024

Buy Rating Reaffirmed for Akero Therapeutics: Strong Financials and Promising Clinical Trials Bolster Confidence

TIPRANKS
·
09 Nov 2024

Akero Therapeutics Q3 Operating Expenses USD 81.7 Million

THOMSON REUTERS
·
08 Nov 2024

Madrigal Pharmaceuticals Shares up 11%, Akero Therapeutics Gains 6% and Viking Therapeutics Shares Rise 2%

THOMSON REUTERS
·
01 Nov 2024

Shares of Some Liver Disease Drugmakers Rise Between 2% and 11% ; Late-Stage Data From Novo's Weight-Loss Drug Shows Improvement in Fatty Liver Disease

THOMSON REUTERS
·
01 Nov 2024

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

GlobeNewswire
·
21 Oct 2024

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin

Insider Monkey
·
16 Oct 2024

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

GlobeNewswire
·
30 Sep 2024